John A. Scarlett, M.D., is a distinguished figure in the field of biotechnology, currently serving as Chairman of the Board, President, and Chief Executive Officer at Geron Corporation. Dr. Scarlett has been with Geron since 2011, initially joining as President and Chief Executive Officer before being appointed Chairman in 2013. His leadership has been instrumental in steering the company towards its mission of developing innovative therapies for cancer and other life-threatening conditions. Prior to his tenure at Geron, Dr. Scarlett amassed a wealth of experience in the pharmaceutical and biotechnology sectors. He previously served as the Chairman, President, and CEO of Proteolix, Inc., a company he co-founded and successfully led until its acquisition by Onyx Pharmaceuticals in 2009. Under his leadership, Proteolix developed Kyprolis® (carfilzomib), a groundbreaking treatment for multiple myeloma, which received accelerated approval from the FDA in 2012. Dr. Scarlett's career also includes significant roles at several other biotech firms, including early-stage venture-backed companies and established industry leaders, where he honed his skills in drug development and corporate strategy. At Geron, Dr. Scarlett oversees the company's strategic direction and operational execution, focusing on advancing the company's lead investigational therapy, imetelstat, through clinical trials. His vision for Geron is to transform the lives of patients with serious diseases by harnessing the potential of telomerase inhibition. Under his guidance, Geron has made significant strides in its clinical programs, positioning the company as a leader in the development of novel cancer treatments. Dr. Scarlett's extensive experience and strategic acumen continue to be pivotal in driving Geron's growth and innovation in the biotechnology industry.